Mosaic ImmunoEngineering is a nanotechnology-based immunotherapy company developing therapeutics and vaccines to positively impact the lives of patients and their families.

Free
Message: What? favorable to the interests of Ptsc shareholder...

This shareholder would like to see some proof that PTSC is working in favor of shareholders!

Q: Regarding the settlement reached between Patriot and the TPL Group in October 2011, why were further details not released regarding the settlement terms?

A: In order for Patriot and TPL to reach a settlement, it was necessary to agree that certain aspects of the settlement for which disclosure was not otherwise required remain confidential. Confidentiality was not our preference, however settling on terms that we believed to be favorable to the interests of Patriot's shareholders was our priority and we believe that we achieved that goal despite our inability to share some of the other details. We hope that by settling we have removed one obstacle faced by the license program.

Q: There were many serious claims levied against TPL by Patriot. How can Patriot simply abandon these claims without moving forward with the litigation?

A: We considered several factors in deciding to settle with TPL, including the significant cost and duration of litigation, the remainder of the MMP Portfolio's patent lives and the disruption to the licensing program. Although no settlement is ever perfect, we believed that the achievements afforded by the settlement were in the best interests of the licensing program and therefore Patriot's shareholders.

Share
New Message
Please login to post a reply